Tuesday, September 8, 2020
Blood & Cancer News:
- Delaying RT for higher-risk prostate cancer found safe: https://bit.ly/2F1cKoQ
Source: https://bit.ly/2FaaMCr
RTOG 9413: https://bit.ly/2DL2FM4
RTOG 9910: https://bit.ly/2F8itJe - HOME-PE trial clarifies which pulmonary embolism patients to treat at home: https://bit.ly/3ibNTN9
- Melanoma experts say ‘no’ to routine gene profile testing: https://bit.ly/2Zka10p
Source: https://bit.ly/2ZkzerB
- VTE, sepsis risk increased among COVID-19 patients with cancer: https://bit.ly/2DL2Wi4
You can learn more about Blood & Cancer at https://www.mdedge.com/podcasts/blood-cancer
How to Listen
Podcast Participants
David Henry, MD, FACP, is a clinical professor of medicine at the University of Pennsylvania and vice chairman of the department of medicine at Pennsylvania Hospital in Philadelphia. He received his bachelor’s degree from Princeton University and his MD from the University of Pennsylvania, then completed his internship, residency, and fellowship at the Hospital of the University of Pennsylvania. After 2 years as an attending in the U.S. Air Force, he was drawn to practicing as a hem-onc because of the close patient contact and interaction, and his belief that, win or lose with each patient, one can always make a difference in their care and lives. Follow Dr. Henry on Twitter: @davidhenrymd. Dr. Henry reported being on the advisory board for Amgen, AMAG Pharmaceuticals, and Pharmacosmos. He reported institutional funding from the National Institutes of Health and FibroGen.